Rilpivirine Tablets — Competitive Intelligence Brief

Rilpivirine Tablets (Rilpivirine Tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-nucleoside reverse transcriptase inhibitor (NNRTI). Area: Infectious Disease.

phase 3 Non-nucleoside reverse transcriptase inhibitor (NNRTI) Reverse transcriptase Infectious Disease Small molecule

Target snapshot

Rilpivirine Tablets (Rilpivirine Tablets) — ViiV Healthcare. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by blocking the replication of the HIV virus.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rilpivirine Tablets TARGET	Rilpivirine Tablets	ViiV Healthcare	phase 3	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	Reverse transcriptase
EFV	EFV	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV reverse transcriptase
Didanosine (enteric-coated)	Didanosine (enteric-coated)	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase
ELV/COBI/FTC/TAF	ELV/COBI/FTC/TAF	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination therapy (integrase inhibitor + NRTI + NtRTI + pharmacokinetic booster)	HIV integrase, HIV reverse transcriptase
Dolutegravir/Lamivudine	Dolutegravir/Lamivudine	Saint Michael's Medical Center	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase
Combivir+Kaletra	Combivir+Kaletra	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + protease inhibitor)	HIV reverse transcriptase and HIV protease
didanosine + lamivudine + efavirenz	didanosine + lamivudine + efavirenz	Clinical Trial Agency of HIV Study Group	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-nucleoside reverse transcriptase inhibitor (NNRTI) class)

1. ViiV Healthcare · 4 drugs in this class
2. National Institute of Allergy and Infectious Diseases (NIAID) · 3 drugs in this class
3. Merck Sharp & Dohme LLC · 2 drugs in this class
4. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
5. Germans Trias i Pujol Hospital · 1 drug in this class
6. International Partnership for Microbicides, Inc. · 1 drug in this class
7. Janssen Infectious Diseases BVBA · 1 drug in this class
8. Janssen-Cilag S.p.A. · 1 drug in this class
9. Johns Hopkins Bloomberg School of Public Health · 1 drug in this class
10. Tibotec Pharmaceuticals, Ireland · 1 drug in this class